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Background: It is widely accepted that metabolic syndrome is associated with an increased risk of chronic kidney
disease (CKD). To investigate whether coexisting metabolic syndrome is a necessary condition for CKD in
overweight and obese.
Methods: A cohort study of 6852 Chinese individuals from August 2007 to December 2012. Examinations included
a questionnaire, physical measurements, and blood sampling. Hazard ratios for incident CKD were estimated
according to combinations of BMI category and absence or presence of metabolic syndrome.
Results: For CKD, multivariable adjusted hazard ratios vs. normal weight individuals without metabolic syndrome
were 1.31 (95 % CI, 0.89–1.92) in overweight and 2.39 (95 % CI, 1.27–4.52) in obese without metabolic syndrome
and 1.54 (95 % CI, 1.18–3.95) in normal weight, 2.06 (95 % CI, 1.27–3.36) in overweight, and 2.77 (95 % CI, 1.42–4.31)
in obese with metabolic syndrome. There were no interactions between BMI and absence or presence of metabolic
syndrome on risk of CKD when BMI was categorized (normal weight, overweight, obese) (P = 0.17). Among
individuals both with and without metabolic syndrome there were increasing cumulative incidences of CKD from
normal weight through overweight to obese individuals (log-rank trend P = 0.04 to P < 0.001). Although the
multivariable adjusted hazard ratio for CKD in individuals with vs. without metabolic syndrome was 1.82 (95 % CI,
1.20–2.78) within overweight and obese individuals (log-rank P = 0.005), only 26.1 % of the increased risk observed
for BMI is explained by metabolic syndrome.
Conclusions: These findings suggest overweight and obesity are risk factors for CKD regardless of the presence or
absence of metabolic syndrome.
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The effects of obesity on kidney function and disease
have since been identified and become a subject of in-
creased study and concern [1–3]. One plausible mechan-
ism for this link is that overweight and obesity often are
accompanied by metabolic syndrome, a cluster of car-
diovascular risk factors consisting of hypertension, dys-
lipidemia, and hyperglycemia [4]. Although there has
been considerable disagreement over the diagnostic cri-
teria of metabolic syndrome [5], it is widely accepted* Correspondence: cx_csu@163.com
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risk of CKD [6–8]. In a large cohort study of >320,000
patients, Hsu et al. [9] found that a higher BMI was a
strong independent risk factor for end stage renal dis-
ease (ESRD) even after adjustment for other major risk
factors that are associated with ESRD, including smok-
ing, baseline hypertension, and diabetes. The question
still remains whether coexisting metabolic syndrome is a
necessary condition for initiating renal injury in over-
weight and obese individuals. Indeed, several studies in-
dicated that obesity may contribute to and perhaps even
initiates glomerulopathy [10, 11]. If this is the case, obes-
ity may be as an independent risk factor for the onset,
aggravated course, and poor outcomes of CKD, evenle distributed under the terms of the Creative Commons Attribution
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ing metabolic syndrome, diabetes and hypertension.
In the present study, we tested the hypothesis that over-
weight and obesity with and without metabolic syndrome
is associated with increased risk of chronic kidney disease.
For this purpose, we studied the occurrence of CKD in
6852 subjects without CKD at baseline 2007 through 2012
in central south China and categorized them according to
their body mass index (BMI) as normal weight, over-




Changsha, the capital city of Hunan province, is a regional
hub in central south China. This was a prospective obser-
vational study based on a convenient sampling of Chinese
urban residents. From August 2007 to December 2012,
10,708 subjects living in this city, between the ages of 20–
79 years who underwent their physical check-ups at the
Health Management Center of the Third Xiangya Hospital
were enrolled in this study. Cohort members in the study
were excluded from these analyses if they had a past or
present history of CVD at baseline (n = 67), were pregnant
(n = 45), were diagnosed with CKD including each of posi-
tive proteinuria (n = 612) and estimated glomerular filtra-
tion rate (eGFR) < 60 mL/min/1.73 m2 (n = 1204) at
baseline, were missing data (n = 1685), or failed to
complete the follow-up health surveys or questionnaires
after the baseline examination (n = 243). After applying
these exclusions, a total of 6852 participants aged 20 to
79 years old were selected. The participation rate was
64 %. Examinations included a questionnaire, physical
measurements, and blood sampling. All participants pro-
vided informed consent before entering the study, and ap-
proval was obtained from the Human Subjects Committee
at the Third Xiangya Hospital, Central South University.
Baseline examinations
Seated blood pressures were measured by skilled, trained
physicians after subjects had rested for 15 min using a
mercury sphygmomanometer according to the American
Heart Association’s recommendations [12]. The average of
3 readings was recorded. Blood samples were collected at
08:00–10:00 AM after a fasting period of 12 h. Concentra-
tions of fasting blood glucose (FBG), total cholesterol (TC),
and triglycerides were determined by enzymatic colorimet-
ric assay. Highdensity lipoprotein cholesterol (HDL-c) con-
centration was measured by lipoprotein electrophoresis.
Low-density lipoprotein cholesterol (LDL-c) concentration
was calculated according to the Friedewald formula. Serum
uric acid was determined by an autoanalyzer using the
phosphotungstate method. Information on antihyperten-
sive medication, antidiabetic treatment, and lipid-loweringtherapy was self-reported. Subjects were identified as
current smokers if they had smoked within 1 year of the
survey date and physical inactivity was defined as leisure
time activity less than 4 h weekly and predominantly sed-
entary work. BMI was calculated as weight (kg) divided by
height squared (m2). Individuals were categorized as nor-
mal weight with a BMI of 18.5 to 23.9, overweight with
BMI of 24.0 to 27.9, and obese with a BMI at least 28.0 ac-
cording to the Chinese standard [13]. Waist circumference
was measured at the midpoint between the lower end of
the rib cage and the upper part of the pelvic bone.
Metabolic syndrome
Metabolic syndrome was defined using the National Chol-
esterol Education Program Adult Treatment Panel III
(NECP-ATP-III) criteria as ≥ 3 of the following 5 metabolic
components: 1) elevated waist circumference: ≥ 90 cm
(males) or ≥ 80 cm (females); 2) elevated triglycerides: ≥
1.69 mmol/l or the use of lipid medications; 3) elevated
blood pressure: systolic blood pressure ≥ 130 mmHg, or
diastolic blood pressure ≥ 85 mmHg, or the use of antihy-
pertensive medications; 4) elevated fasting glucose: ≥
5.6 mmol/l or the use of diabetes medications; 5) reduced
HDL-c: < 1.04 mmol/l (male) or < 1.29 mmol/l (female) [5].
Definition of CKD
Serum creatinine (Scr) was measured on a Roche/Hitachi
Modular System P (Roche Diagnostics GmbH, Mannheim,
Germany) by creatinine Jaffe rate blanked and compen-
sated assay. To ensure quality control creatinine was mea-
sured in 40 samples with creatinine both at the central
laboratory in Hunan province and at the laboratory of Pe-
king University First Hospital. Renal function was esti-
mated by calculated glomerular filtration rate (eGFR)
using a modified Chinese equation based on inulin clear-
ance as follows: eGFR (mL/min/1.73 m2) = 175 × (Scr in
enzymatic method)-1.234 × age - 0.287 (×0.79, if female) [14].
Diagnosis of proteinuria was made using a urine dipstick
test. Positive proteinuria was considered to be present for
a dipstick result of ≥ 1+, corresponding to a urinary pro-
tein level > 30 mg/dL [15]. CKD was defined as positive
proteinuria or eGFR < 60 mL/min/1.73 m2.
Follow-up and outcomes
Primary outcomes were defined as the onset of CKD at
the time of the annual check-up from 2007 to 2012. If a
participant experienced more than one CKD event dur-
ing follow-up, only the first outcome for the individual
contributed to the outcome analysis. The date of onset
of CKD was defined as the midpoint between the last
date when the subjects did not have CKD and the first
date when the subject was diagnosed with CKD. The
follow-up period was defined as the number of days
from the date of observation to the date of CKD
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an eGFR < 60 mL/min/1.73 m2 or an isolated positive
proteinuria were analyzed as individual primary out-
comes. Secondary outcomes were defined as a composite
of CKD or death from all causes.
Statistical analyses
All statistical analyses were conducted using SAS soft-
ware, version 8.1 (SAS Institute, Inc.). Analyses of vari-
ances and χ2 tests were used to compare mean values
and frequencies. Cumulative incidences were plotted
using Kaplan-Meier curves and a log-rank test was used
to compare incidence curves. Cox proportional hazards
regression models estimated hazard ratios (HRs) for
CKD multifactorially adjusted for age, sex, smoking,
plasma low-density lipoprotein cholesterol level, antihy-
pertensive/lipid-lowering/antidiabetic medication use,
and physical inactivity and the probability value for
homogeneity was estimated by adding an interaction
term to the statistical model. The percentage of excess
risk of CKD for a basic model including BMI and clinical
characteristics that was explained by metabolic syndrome
was calculated by using the formula: percentage excess
risk = [(HRcon adj −HRcon + med adj)/(HRcon adj − 1)] ×
100 %, where HRcon adj is the confounder-adjusted HR for
CKD and HRcon + med adj is the confounder and mediator–
adjusted HR [16].
Results
Baseline characteristics of the 6852 individuals included
in the study are seen in Table 1 stratified by BMI cat-
egory (normal weight, overweight, obese) and by the ab-
sence or presence of metabolic syndrome. Among these,
3864 individuals (56.4 %) were normal weight, 2508
overweight (36.6 %), and 480 individuals (7.0 %) were
obese. Metabolic syndrome was present in 6.0 % of nor-
mal weight, in 26.2 % of overweight, and in 57.5 % of
obese individuals. Characteristics stratified by sex are
shown in Tables 2. Among the 3704 male participants,
1432 were normal weight (38.7 %), 1876 were over-
weight (50.6 %), and 396 individuals (10.7 %) were obese.
Corresponding numbers among the 3148 female partici-
pants were 2432 (77.3 %), 632 (20.1 %), and 84 (2.7 %),
respectively.
During an average 54.3-month follow-up period, Of
the 6852 participants, the number of patients with onset
of CKD was 776 subjects, which included solely an
eGFR < 60 mL/min/1.73 m2 in 520 (67.0 %) subjects,
isolated positive proteinuria in 180 (23.2 %) subjects and
both criteria in 76 (9.8 %) subjects. As expected, the cu-
mulative incidences of CKD were higher in overweight
and obese vs. normal weight individuals (both log-rank
trend P < 0.001) (Fig. 1a). Multivariable adjusted HRs for
CKD vs. normal weight individuals were 2.04 (95 % CI,1.50–2.78) in overweight and 3.76 (95 % CI, 2.47–5.71)
in obese individuals. Also, the presence of metabolic
syndrome was associated with increased cumulative inci-
dences of CKD (log-rank P < .001) (Fig. 1b). Multivari-
able adjusted HRs for CKD in individuals with vs.
without metabolic syndrome was 2.42 (95 % CI, 1.74–
3.37). Risk of CKD increased stepwise according to the
presence of 1, 2, 3, 4, or 5 components of metabolic
syndrome (Fig. 1c). The HRs for CKD in individuals vs.
with none components of metabolic syndrome were 1.24
(95 % CI, 1.03–1.58), 1.86 (95 % CI, 1.21–2.62), 3.12 (95 %
CI, 1.51–6.25), 3.48 (95 % CI, 1.66–7.02), and 5.69 (95 %
CI, 2.32–10.31) with one, two, three, four, and five compo-
nents of metabolic syndrome individuals, respectively.
The HRs was adjusted for age, sex, smoking, plasma low-
density lipoprotein cholesterol level, antihypertensive/
lipid-lowering/antidiabetic medication use, and physical
inactivity.
When individuals were divided into groups according
to their BMI category (normal weight, overweight, obes-
ity) and absence or presence of metabolic syndrome, risk
of CKD increased with higher BMI category independent
of presence or absence of metabolic syndrome (Table 3).
For CKD, multivariable adjusted HRs vs. normal weight
individuals without metabolic syndrome were 1.31 (95 %
CI, 0.89–1.92) in overweight and 2.39 (95 % CI, 1.27–
4.52) in obese individuals without metabolic syndrome
and 1.54 (95 % CI, 1.18–3.95) in normal weight, 2.06
(95 % CI, 1.27–3.36) in overweight, and 2.77 (95 % CI,
1.42–4.31) in obese individuals with metabolic syn-
drome. There were no interactions between BMI and ab-
sence or presence of metabolic syndrome on risk of
CKD when BMI was categorized (normal weight, over-
weight, obese) (P = 0.17). Stratifying for sex gave slightly
higher risk estimates for CKD in men but attenuated re-
sults in women.
Among individuals without metabolic syndrome, there
were increasing cumulative incidences of CKD from nor-
mal weight through overweight to obese individuals
(log-rank trend P < 0.001) (Fig. 2a). The hazard ratios
(HRs) for chronic kidney disease (CKD) vs. normal
weight individuals without metabolic syndrome were
1.82 (95 % CI, 1.36–2.42) in overweight and 3.82 (95 %
CI, 2.47–6.12) in obese individuals without metabolic
syndrome. Among individuals with metabolic syndrome,
there likewise were increasing cumulative incidences of
CKD from normal weight through overweight to obese
individuals (log-rank trend P = 0.04) (Fig. 2b). The HRs
for CKD vs. normal weight individuals with metabolic
syndrome were 1.27 (95 % CI, 1.02–1.68) in overweight
and 2.36 (95 % CI, 1.35–3.86) in obese individuals with
metabolic syndrome. Within overweight and obese indi-
viduals, presence vs. absence of metabolic syndrome was
associated with increased cumulative incidences of CKD
Table 2 Baseline Characteristics of Participants According to Body Mass Index Categories and Sex
Characteristic Male Female
Normal Weight Overweight Obese Normal Weight Overweight Obese
Participants, No. 1432 1876 396 2432 632 84
Age, median (IQR), y 40 (32–53) 48 (38–56) 46 (39–55) 39 (33–45) 47 (39–53) 48 (44–53)
BMI, median (IQR), Kg/m2 22.4 (21.0–23.2) 25.7 (24.8–26.7) 29.1 (28.4–30.0) 20.9 (19.7–22.2) 25.4 (24.6–26.4) 29.7 (28.6–31.6)
Waist circumference, median (IQR), cm 78 (76–81) 82 (78–86) 88 (80–94) 71 (66–80) 80 (77–82) 84 (80–87)
Systolic BP, median (IQR), mm Hg 120 (114–130) 126 (118–138) 130 (120–142) 108 (100–118) 120 (114–134) 124 (112–138)
Diastolic BP, median (IQR), mm Hg 74 (66–82) 80 (74–88) 82 (76–90) 68 (60–74) 76 (68–82) 84 (74–88)
Antihypertensive, % 3.4 9.6 18.2 1.1 6.3 23.8
Antidiabetes, % 3.1 3.0 1.0 0.5 1.3 0
Lipid-lowering 3.8 8.1 10.2 1.3 5.2 5.8
TC, median (IQR), mmol/L 4.5 (4.0–5.1) 4.7 (4.2–5.3) 5.0 (4.3–5.4) 4.4 (3.9–4.8) 4.6 (4.1–5.3) 4.9 (4.3–5.2)
LDL-c, median (IQR), mmol/L 2.5 (2.0–3.0) 2.6 (2.1–3.1) 2.6 (2.0–3.0) 2.3 (1.9–2.7) 2.7 (2.1–3.2) 2.5 (2.1–3.0)
HDL-c, median (IQR), mmol/L 1.3 (1.2–1.5) 1.2 (1.0–1.4) 1.1 (1.0–1.3) 1.6 (1.4–1.8) 1.4 (1.2–1.6) 1.4 (1.2–1.7)
Triglycerides, median (IQR), mmol/L 1.2 (0.9–1.8) 1.7 (1.2–2.4) 2.3 (1.6–2.9) 0.9 (0.7–1.1) 1.3 (0.9–1.7) 1.6 (1.2–1.8)
Glucose, median (IQR), mmol/L 4.7 (4.4–5.1) 4.9 (4.6–5.3) 5.1 (4.7–5.6) 4.7 (4.4–5.0) 4.9 (4.5–5.3) 5.1 (4.8–5.4)
eGFR, median (IQR), mL/min/1.73 m2 79 (72–91) 77 (70–87) 78 (71–86) 119 (102–139) 114 (98–133) 121 (93–129)
Current smokers, % 36.9 36.9 33.3 0.3 0 0
Physical inactivity, % 46.9 48.5 50.1 38.1 55.1 61.3
Abbreviations: BMI body mass index, IQR interquartile range, BP blood pressure, TC total cholesterol, LDL-c Low-density lipoprotein cholesterol, HDL-c high-density
lipoprotein cholesterol
Table 1 Baseline Characteristics of Participants According to Body Mass Index Categories and Presence or Absence of Metabolic
Syndrome
Characteristic Without Metabolic Syndrome With Metabolic Syndrome
Normal Weight Overweight Obese Normal Weight Overweight Obese
Participants, No. 3632 1852 204 232 656 276
Female, % 63.3 23.5 15.7 56.9 29.9 18.8
Age, median (IQR), y 39 (32–47) 47 (37–54) 49 (39–55) 50 (40–60) 49 (42–56) 45 (40–53)
BMI, median (IQR), Kg/m2 21.4 (20.0–22.7) 25.4 (24.7–26.4) 29.1 (28.2–29.9) 22.7 (21.2–23.3) 26.2 (25.3–27.1) 29.2 (28.5–30.3)
Waist circumference, median (IQR), cm 75 (68–80) 81 (78–84) 86 (80–92) 80 (78–84) 82 (80–88) 90 (80–96)
Systolic BP, median (IQR), mm Hg 112 (104–122) 122 (114–134) 125 (116–138) 125 (118–138) 130 (122–142) 132 (124–142)
Diastolic BP, median (IQR), mm Hg 69 (62–76) 78 (70–85) 78 (73–88) 80 (71–87) 83 (78–89) 84 (79–90)
Antihypertensive, % 1.9 6.3 15.7 3.4 15.9 21.7
Antidiabetes, % 1.0 2.2 2.8 8.6 3.7 9.8
Lipid-lowering, % 1.4 2.6 5.1 7.8 8.2 10.2
TC, median (IQR), mmol/L 4.4 (3.9–4.9) 4.6 (4.1–5.2) 4.8 (4.2–5.2) 5.1 (4.5–5.8) 4.8 (4.3–5.6) 5.1 (4.4–5.7)
LDL-c, median (IQR), mmol/ L 2.3 (1.9–2.8) 2.6 (2.2–3.1) 2.6 (2.0–3.0) 2.8 (2.3–3.5) 2.5 (1.9–3.2) 2.6 (2.0–3.2)
HDL-c, median (IQR), mmol/L 1.5 (1.3–1.7) 1.3 (1.1–1.5) 1.3 (1.1–1.4) 1.2 (1.0–1.5) 1.1 (1.0–1.3) 1.1 (0.9–1.3)
Triglycerides, median (IQR), mmol/L 0.9 (0.7–1.3) 1.3 (1.0–1.8) 1.5 (1.2–2.2) 1.7 (1.1–2.2) 2.3 (1.8–3.1) 2.4 (1.9–3.0)
Glucose, median (IQR), mmol/L 4.7 (4.4–5.0) 4.8 (4.5–5.2) 4.9 (4.8–5.2) 5.4 (4.7–5.9) 5.3 (4.8–5.8) 5.2 (4.7–6.2)
eGFR, median (IQR), mL/min/1.73 m2 104 (82–127) 82 (71–99) 78 (72–93) 90 (76–108) 82 (72–99) 81 (74–90)
Current smokers, % 6.2 29.2 25.5 17.2 23.2 30.0
Physical inactivity, % 39.2 51.0 56.6 46.6 52.4 52.2
Abbreviations: BMI body mass index; IQR, interquartile range; BP blood pressure; TC total cholesterol; LDL-c Low-density lipoprotein cholesterol; HDL-c high-density
lipoprotein cholesterol
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Fig. 1 Kaplan-Meier curves for the cumulative incident of chronic kidney disease (CKD) according to body mass index (BMI) category and
metabolic syndrome. a The hazard ratios (HRs) for chronic kidney disease (CKD) according to body mass index (BMI) category. b The HRs for CKD
according to metabolic syndrome. c The HRs for CKD according to the components of metabolic syndrome
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HR (95 % CI)
Normal weight No 3632 284 1 1332 185 1 2300 99 1
Overweight No 1852 248 1.31 (0.89–1.92) 1416 229 1.84 (1.31–2.59) 436 19 1.05 (0.87–1.25)
Obese No 204 56 2.39 (1.27–4.52) 172 49 3.65 (2.06–5.17) 32 7 1.23 (0.95–1.52)
Normal weight Yes 232 16 1.54 (1.18–3.95) 100 11 2.19 (1.80–3.66) 132 5 0.88 (0.71–1.27)
Overweight Yes 656 104 2.06 (1.27–3.36) 460 93 3.13 (1.99–4.90) 196 11 1.35 (1.12–1.64)
Obese Yes 276 68 2.77 (1.42–4.31) 224 65 4.08 (2.40–5.92) 52 3 1.41 (1.22–1.71)
Hazard ratios were adjusted for age, sex, smoking, plasma low-density lipoprotein cholesterol level, medication use, and physical inactivity. Abbreviations: 95 % CI
95 % confidence interval, HR hazard ratio, CKD chronic kidney disease
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without metabolic syndrome was 1.24 (95 % CI, 1.03–
1.58) in overweight and obese individuals.
As shown in Additional file 1: Table S1, the percentage
of excess risk mediated by metabolic syndrome in the
association between BMI (as a continuous variable) and
CKD was 26.1 %; that is, 26.1 % of the associated effect
size of BMI on risk of CKD is explained by metabolic
syndrome. When BMI was categorized (normal weight,
overweight, obese), this proportion increased to 33.3 %.
Discussion
In this cohort study of a general urban Chinese popula-
tion, the risk for CKD in overweight and obesity was sig-
nificantly increased independent of the presence or
absence of metabolic syndrome.
Some experimental and clinical evidence have recently
implicated a causal link between increased BMI and in-
creased risk of CKD [17, 18]. The suggested mechanism
for this link is through obesity-related risk factors such
as hypertension, dyslipidemia, and hyperglycemia, all
components of metabolic syndrome [19]. Indeed, our
findings in the present study may be explained by over-
weight and obese individuals without metabolic syn-
drome at baseline developing the other components of
the syndrome over time, which later leads to renal in-
jury. In support of this hypothesis, abdominal obesity
often precedes the other components [20, 21] and may
even be causal in the development of other CKD risk
factors such as hypertension [22]. Previous studies have
shown that BMI was relatively higher within each BMI
category in individuals with metabolic syndrome [23, 24],
and this may explain some of the excess risk observed
in these individuals compared with those without
metabolic syndrome. Also, the addition of metabolic
syndrome only slightly increased the capacity of BMI
and other clinical characteristics to predict CKD. This
was also supported by mediation analyses, which suggestedthat only a minor proportion of the increased risk ob-
served for BMI is explained by metabolic syndrome.
Thus, although the presence of metabolic syndrome in-
creases CKD risk, these associations are not strong and
are similar to associations noted between overweight
and obesity and incident CKD. This finding has clinical
relevance. At subject visits for health care, BMI can
easily and accurately be determined with the use of
minimum equipment, which would allow the immedi-
ate identification of individual at heightened risk that
might benefit from therapeutic lifestyle intervention
aimed at weight control.
Foster et al. [25] found obesity is associated with in-
creased risk of developing stage 3 CKD, which was no
longer significant after adjustment for known cardiovas-
cular disease risk factors. In contrast, several studies
have found an increased risk of CKD in overweight and
obese even after adjustment for baseline covariates [18, 26].
The inconsistencies between these former studies may be
caused by differences in defining CKD and/or the cohort
selection criteria. Also, studies with small sample sizes or a
low number of events may not have enough statistical
power to discriminate the differences. To our knowledge,
the present study is the largest to date including both men
and women in different age groups in Chinese. Our find-
ings suggest that overweight and obesity even in the ab-
sence of metabolic syndrome are not benign conditions for
renal function.
Obesity may contribute to the development of CKD
through pathways related to insulin resistance that can
cause renal injury, such as activation of the renin-
angiotensin-aldosterone system, activation of insulin/in-
sulin-like growth factor-1 signaling pathways, oxidative
stress, suppression of peroxisome proliferatoractivated
receptor gamma, inflammation-related tissue damage,
nephrosclerosis, and activation of the renal sympathetic
system [4, 27]. The glomerular hypertension/hyperfiltra-
tion hypothesis as a trigger of CKD progression in
Fig. 2 Kaplan-Meier curves for the cumulative incident of chronic kidney disease (CKD) by body mass index category stratified by the absence/
presence of the metabolic syndrome. a The hazard ratios (HRs) for chronic kidney disease (CKD) by body mass index category without metabolic
syndrome. b The HRs for CKD by body mass index category with metabolic syndrome. c The HRs for CKD with vs. without metabolic syndrome
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[28]. Meanwhile, there is mounting evidence that lipids
accumulation and alterations in fat cells cytokines can
translate into inflammatory changes in the kidney [4].
Some limitations of our study must be considered in
evaluating our results. Firstly, our study took place in a
single center from a large urban teaching hospital, and
the study populations were participants of an annual
health check-ups could lead to selection bias due to pos-
sible overrepresentation of relatively healthy overweight
and obese individuals. Another limitation is that we did
not have detail on medication may tend to underesti-
mate the potential effect of agents. Finally, the diagnosis
of CKD in the present study depended on the value of
creatinine or positive proteinuria on only one occasion
and is accordingly more prone to misclassification.
As a global public health problem, obesity is a princi-
pal causative factor in the development of metabolic
syndrome. However, based on the present data, it is rea-
sonable to suggest that even in the absence of metabolic
syndrome, public health strategies should focus on help-
ing individuals to reduce their exposure to an obesity-
promoting environment.
Also, because abdominal adiposity seems to precede
the development of the other abnormalities in the syn-
drome, overweight and obesity may in some individ-
uals be an early warning sign for future metabolic
disturbances. Animal models have shown that caloric
restriction retards kidney injury and these effects may
be mediated by up-regulation of Sirt1 expression which
is expressed abundantly in the renal inner medulla and
in medullary interstitial cells and likely protects me-
dullary interstitial cells from oxidative stress [29, 30].
In addition to this study, in humans with CKD, non-
surgical weight loss interventions reduce proteinuria
and blood pressure [31]. Moreover, in morbidly obese
individuals with glomerular hyperfiltration bariatric
surgeries normalize GFR and reduce blood pressure
and microalbuminuria [32]. In addition, the antiproteinu-
ric effect of ACE seems to be maximal in overweight/
obese patients and less prominent in patients with nor-
mal BMI, suggesting role of glomerular hyperfiltration
in pathogenesis of proteinuria in obesity [33]. Thus,
weight loss and long-term maintenance of that weight
loss might be encouraged in overweight and obese
individuals, regardless of presence or absence of meta-
bolic syndrome, to reduce risk of obesity-related renal
injury.
Conclusion
In conclusion, overweight and obesity with and without
metabolic syndrome are associated with increased risk of
CKD in the general population. These findings suggest
that overweight and obesity even in the absence ofmetabolic syndrome are not benign conditions and that
weight loss might be encouraged regardless of the pres-
ence or absence of metabolic syndrome to reduce the
burden of CKD. Our findings also suggest that the pres-
ence of metabolic syndrome increases CKD risk, associa-
tions are not strong and are similar to associations
noted between overweight and obesity and incident
CKD however. Although hypertension and diabetes are
important mediators, additional pathways also may exist.
More clinical trials are needed to assess the impact of
overweight and obesity on kidney disease incidence and
progression.
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